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Abstract: A series of novel diflunisal hydrazide-hydrazones has been reported together with
their anti-hepatitis C virus and antiproliferative activities in a number of human hepatoma
cell lines. However, the mechanisms underlying the efficacy of these agents remain unclear.
It was chosen to investigate the lead diflunisal hydrazide-hydrazone, 2′,4′-difluoro-4-hydroxy-N′-
[(pyridin-2-yl)methylidene]biphenyl-3-carbohydrazide (compound 3b), in two cultured human
hepatoma cell lines—HepG2 and Hep3B—using a metabolomic protocol aimed at uncovering any
effects of this agent on cellular metabolism. One sub-therapeutic concentration (2.5 µM) and one close
to the IC50 for antimitotic effect (10 µM), after 72 h in cell culture, were chosen for both compound 3b
and its inactive parent compound diflusinal as a control. A GCMS-based metabolomic investigation
was performed on cell lysates after culture for 24 h. The intracellular levels of a total of 42 metabolites
were found to be statistically significantly altered in either HepG2 or Hep3B cells, only eight of
which were affected in both cell lines. It was concluded that compound 3b affected the following
pathways—purine and pyrimidine catabolism, the glutathione cycle, and energy metabolism through
glycolysis and the pentose phosphate pathway. Although the metabolomic findings occurred after
24 h in culture, significant cytotoxicity of compound 3b to both HepG2 and Hep3B cells at 10 µM
were reported not to occur until 72 h in culture. These observations show that metabolomics can
provide mechanistic insights into the efficacy of novel drug candidates prior to the appearance of
their pharmacological effect.
Keywords: diflunisal; hydrazone; antihepatitis C virus; antiproliferative; metabolomics; metabolic
networks
1. Introduction
It is now well understood that the vast majority of diseases involve altered patterns of cellular
metabolites. Cancer has been well studied in this regard, particularly with respect to energy metabolism.
Glucose, glutamine, acetate, lactate, pyruvate, hydroxybutyrate, and fatty acids may all be metabolized
faster in malignant tissues than in their non-tumor counterparts [1]. Altered metabolism in cancer
cells is viewed as now providing potentially new therapeutic targets [2]. Moreover, these so-called
metabolic hallmarks of cancer cells are believed to lead to an altered interplay between immune cells
and tumor cells that can lead to immunosuppression. The view has been expressed that metabolic
reeducation of cancer cells may not only assist in direct tumor cytotoxicity, but also attenuate metabolic
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immunosuppression in the tumor microenvironment, thus facilitating immunotherapy [3]. In addition,
lipid signaling pathways can also be altered in various cancers. For example, we have recently
reported that a significant number of lipid groups, including prostaglandins and their precursors,
phosphocholines, fatty acids, sphingolipids, triglycerides, together with cholesterol and its esters,
are all altered in the plasma of patients presenting with acute myeloid leukemia [4]. Finally, chronic
viral infection that can lead to cancer, such as with hepatitis C virus (HCV), can provoke profound
metabolic alterations in hepatocytes [5] that can be detected in plasma and urine through metabolomic
investigation [6]. Understanding how host cell metabolic pathways can be hijacked by oncogenic
viruses and ultimately by cancer cells should offer new avenues for therapy. Furthermore, insights into
the effects of new therapeutic agents on the metabolism of virus-infected cells and tumors is expected
to lead to improved therapeutic solutions.
HCV infection is a major global health problem with an estimated 150–160 million people assumed
to be infected, approximately 3% of the world’s population [7,8]. Chronic hepatitis C leads to fibrotic
changes in the liver, and ultimately to cirrhosis, after the development of which, the patient has a
high risk of developing hepatocellular carcinoma (HCC). The goal of HCV treatment has been to
eradicate the infection, thereby terminating the chronic liver inflammation and, thus, decreasing
the complications that can follow cirrhosis [7]. Interferon-α (IFN) combined with ribavirin (RBV)
was the mainstay of HCV treatment but more recently so-called direct acting antivirals (DAAs)
have been developed that have, in part, replaced IFN/RBV-based treatments. The first generation
comprised protease inhibitors (boceprivir and telaprevir), then the HCV NS5B RNA polymerase
inhibitor (sofosbuvir) and the NS5A replication complex inhibitor (daclatasvir) [8]. Resistance to
DDAs is a growing clinical problem that is incompletely understood [9]. Accordingly, there is clearly
a need for the development of further clinically- and cost-effective anti-HCV drugs with a high
threshold to resistance. Additionally, chemotherapeutic options for HCC are limited. Many clinical
trials have ended in failure [10]. The most commonly used agent is sorafenib, which is a drug that
inhibits serine-threonine kinases Raf-1 and B-Raf, the receptor tyrosine kinase activity of vascular
endothelial growth factor receptors (VEGFRs) 1, 2, and 3, and platelet-derived growth factor receptor b
(PDGFR-b) [11,12]. Sorafenib, therefore, inhibits both tumor cell proliferation and angiogenesis. New
and effective candidate chemotherapeutic agents for the treatment of HCC are also required.
A series of novel derivatives of the non-steroidal anti-inflammatory drug (NSAID) and the
analgesic agent diflunisal have been reported that possess both inhibition of HCV replication
and dose-dependent antiproliferative activity in a range of hepatoma cell lines [13]. Diflunisal
derivatives have frequently been reported to possess several biological activities, including
anticancer, anti-HIV, anticonvulsant, antimicrobial, and anti-inflammatory properties [13]. Of this
series, 2′,4′-difluoro-4-hydroxy-N′-[(pyridin-2-yl)methylidene]biphenyl-3-carbohydrazide (termed
compound 3b; Figure 1) displayed IC50 values in the 5–15 µM range for cell cycle arrest and
apoptotic cell death in six hepatoma cell lines [13]. Currently, the mechanisms that underlie these
effects are unknown. We have, therefore, conducted a gas chromatography-mass spectrometry
(GCMS)-based metabolomic investigation of compound 3b and diflunisal in two HCC-derived cell
lines, HepG2 and Hep3B in order to discover metabolic pathways that might be perturbed in relation
to the antiproliferative and proapoptotic properties of compound 3b. We chose not to study drug
effects on primary human hepatocytes (PHHs) since there were no data in the original study [13].
In addition, PHHs from different donors have been reported to display wide interindividual variation
in metabolic activity [14] that also can vary considerably with respect to culture time, even in the
first 24 h [15]. Metabolomic data collected in HepG2 and Hep3B hepatoma cell lines are expected to
reveal novel insights into the pharmacological effects of the lead compound 3b, which is intended to
be active against hepatocellular carcinoma. When healthy liver tissue is the disease target, as with
paracetamol/acetaminophen toxicity, studies in PHHs are more applicable [14].
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Figure 1. (a) Diflunisal; (b) 2′,4′-Difluoro-4-hydroxy-N′-[(pyridin-2-yl)methylidene]biphenyl- 
3-carbohydrazide (compound 3b). 
2. Results 
2.1. Metabolomic Analysis—Compound 3b versus Diflunisal 
In the discovery experiments, metabolomic analysis of compound 3b versus diflunisal (four 
flasks vs. four flasks) at 10 μM in both HepG2 and Hep3B cells revealed clustering and separation of 
the two treatments in the projection to latent structures-discriminant analysis (PLS-DA) scores plot 
for HepG2 cells (Figure 2) [6,16,17]. A leave-one-out cross-validation [6,16,17] was conducted to 
determine that the PLS-DA model was valid (Figure 2). Orthogonal PLS-DA (OPLS-DA) analysis 
was performed to reveal the differential metabolites that drove the separation of compound 3b and 
diflunisal metabolomic phenotypes in Figure 2. An OPLS-DA loadings S-plot (Figure 2) [6,16,17] 
shows cellular metabolites that were both upregulated and attenuated in HepG2 cells by treatment 
with compound 3b, relative to diflunisal treatment. These metabolite levels were subjected to 
univariate statistics and the results are shown in Table 1, combined with validation findings for 10 
μM diflunisal (control) vs. 10 μM compound 3b (5 vs. 5). Similarly, the metabolite data from treated 
Hep3B cells was also subjected to PLS-DA (Figure 3) and OPLS-DA (Figure 3) analysis. It is 
noteworthy that the PLS-DA score plots for HepG2 (Figure 2) and Hep3B (Figure 3) are similar. 
However, in the OPLS-DA loadings S-plots (Figures 2 and 3), there occurred more upregulated 
metabolites for the HepG2 than the Hep3B cell incubations with compound 3b and, conversely, 
more downregulated metabolites for Hep3B than HepG2 incubations. The augmented and 
diminished cellular metabolites in Hep3B cells were also subjected to univariate statistical analysis 
with the results given in Table 1 alongside the HepG2 findings. 
 
Figure 2. Metabolomic analysis of HepG2 cellular metabolites after treatment with compound 3b and 
diflunisal in discovery experiments. (a) PLS-DA score plot showing clustering and separation of 
metabolomic data from four culture flasks with compound 3b and four with diflunisal (control); (b) 
leave-one-out cross-validation of PLS-DA model where R2 is the correlation coefficient and Q2 the 
predictability coefficient; (c) OPLS-DA loadings S-plot where each point represents a metabolite and 
the red and green boundary boxes enclose cellular metabolites that are up- and downregulated, 
respectively, by compound 3b; and (d) PLS-DA scores plot for HepG2 cellular metabolites after 
treatment with compound 3b at 0, 2.5, and 10 μM. 
Figure 1. (a) Diflunisal; (b) 2′,4′-Difluoro-4-hydroxy-N′-[(pyridin-2-yl)methylidene]biphenyl-3-carbohydrazide
(compound 3b).
2. Results
2.1. Metabolomic Analysis—Compound 3b versus Diflunisal
In the disc very experiments, metabolomic analysis of compound 3b versus diflunis l (f ur lasks
vs. four flasks) t 10 µM in both HepG2 and Hep3B cells revealed clustering and separati n of the two
treatments in the projection to latent structures-discriminant analysis (PLS-DA) scores plot for HepG2
cells (Figure 2) [6,16,17]. A leave-one-out cross-validation [6,16,17] was conducted to determine that
the PLS-DA model was valid (Figure 2). Orthogonal PLS-DA (OPLS-DA) analysis was performed to
reveal the differential metabolites that drove the separation of compound 3b and diflunisal metabolomic
phenotypes in Figure 2. An OPLS-DA loadings S-plot (Figure 2) [6,16,17] shows cellular metabolites
that were both upregulated and attenuated in HepG2 cells by treatment with compound 3b, relative to
diflunisal treatment. These metabolite levels were subjected to univariat statistics and the results are
shown in Tabl 1, combined with validation findings for 10 µM diflunisal (control) vs. 10 µM compound
3b (5 vs. 5). Simil rly, the metabolite data from treated Hep3B cells was also subjected to PLS-DA
(Figure 3) and OPLS-DA (Figure 3) analysis. It is noteworthy that the PLS-DA score plots for HepG2
(Figure 2) and Hep3B (Figure 3) are similar. However, in the OPLS-DA loadings S-plots (Figures 2 and 3),
there occurred more upregulated metabolites for the HepG2 than the Hep3B cell incubations with
compound 3b and, conversely, more downregulated metabolites for Hep3B than HepG2 incubations.
The augmented and diminished cellular metabolites in Hep3B cells were also subjected to univariate
statistical analysis with the results given in Table 1 alongside the HepG2 findings.
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Figure 2. Metabolomic analysis of HepG2 cellular metabolites after treatment with compound 3b
and diflunisal in discovery experiments. (a) PLS-DA score plot showing clustering and separation
of metabolomic data from four culture flasks with co pound 3b and fo r with iflunisal (control);
(b) leave-one-out cross-validation of PLS-DA model where R2 is the correlation coefficien and Q2 the
predictability coefficient; (c) OPLS-DA lo dings S-plot where each point represents a metabolite and the
red and green boundary boxes enclose cellular metabolites that are up- and downregulated, respectively,
by compound 3b; and (d) PLS-DA scores plot for HepG2 cellular metabolites after treatment with
compound 3b at 0, 2.5, and 10 µM.
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Table 1. Univariate statistics for both HepG2 and Hep3B cells treated with compound 3b or
diflunisal (control).
Metabolite Retention Time (min) Derivatives Formed HMDB Number HepG2 Hep3B
Ethanolamine
9.26 2TMS
00149 ↓↓↓12.94 3TMS
Glycolic acid 9.97 2TMS 00115 ↓↓
Glycine 10.67 2TMS 00123 ↑13.54 3TMS
Valine 12.18 2TMS 00883 ↓
Leucine 12.99 2TMS 00687 ↓
Isoleucine 13.32 2TMS 00172 ↓
Proline 13.41 2TMS 00162 ↓
Succinic acid 13.53 2TMS 00254 ↓
Glyceric acid 13.83 3TMS 00139 ↑↑
Uracil 13.96 2TMS 00300 ↑↑↑↑
Serine 14.24 3TMS 00187 ↓
Threonine 14.62 3TMS 00167 ↓
Aminomalonic acid 15.73 3TMS 01147 ↓
Erythritol 16.20 4TMS 02994 ↓↓
Aspartic acid 16.32 3TMS 00191 ↓↓↓
5-Oxoproline 16.40 2TMS 00267 ↑↑↑↑ ↓
Erythronic acid 16.67 4TMS 00613 ↓↓
Cysteine 16.79 3TMS 00574 ↑ ↓
Creatinine 16.87 3TMS 00562 ↓ ↓
2-Oxoglutaric acid 16.96 2TMS; 1MOX 00208 ↑
Ornithine 17.44 3TMS 00214 ↓
Glutamic acid 17.50 3TMS 00148 ↑↑↑↑ ↓
Phenylalanine 17.68 2TMS 00159 ↓
N-Acetylaspartic acid 18.11 3TMS 00812 ↓
Lysine 18.50 3TMS 00182 ↑↑↑ ↓20.82 4TMS
Xylitol 18.78 5TMS 02917 ↓
Glycerol 3-phosphate 19.19 4TMS 00126 ↓
Glutamine 19.25 3TMS 00641 ↓↓
Hypoxanthine 19.66 2TMS 00157 ↑↑↑
Galactose
20.61 5TMS; 1MOX
00143 ↑21.08 5TMS; 1MOX
Tyrosine 21.02 3TMS 00158 ↑↑ ↓
Pantothenic acid 21.55 3TMS 00210 ↑↑↑↑
Myo-inositol 22.64 6TMS 00211 ↓
Phosphoglycolic acid 22.72 3TMS 00816 ↓
Ribose 22.76 5TMS; 1MOX 00283 ↑↑↑
Oleic acid 23.46 1TMS 00207 ↓
Fructose 6-phosphate 24.59 6TMS; 1MOX 00124 ↑↑↑↑ ↑
Glucose 6-phosphate 24.71 6TMS; 1MOX 01401 ↑↑↑↑ ↑
Arachidonic acid 24.80 1TMS 01043 ↓
Sedoheptulose
7-phosphate 24.88 7TMS; 1MOX 01068 ↑↑↑↑
Uridine 25.63 3TMS 00296 ↑
Guanosine 28.38 5TMS 00133 ↑↑
↑, ↑↑, ↑↑↑, and ↑↑↑↑ means an increase for compound 3b relative to diflunisal (p < 0.05; p < 0.01; p < 0.001;
and p < 0.0001, respectively). ↓, ↓↓, ↓↓↓, and ↓↓↓↓means a decrease for compound 3b relative to diflunisal (p < 0.05;
p < 0.01; p < 0.001; and p < 0.0001, respectively). TMS means trimethylsilyl derivative. MOX means O-methyloxime
derivatives of ketones and aldehydes. HMDB is the Human Metabolome Database [18].
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Figure 3. Metabolomic analysis of Hep3B cellular metabolites after treatment with compound 3b and
diflunisal. (a) PLS-DA score plot showing clusteri and separation f metabolomic data from four
culture flasks with pound 3b and four with diflunisal (control); (b) le ve-one-out cross-validation of
PLS-DA model where R2 is the correlation coefficient and Q2 the predictability coefficient; (c) OPLS-DA
loadings S-plot where each point represents a metabolite and the red and green boundary boxes enclose
cellular metabolites that are up- and downregulated, respectively, by compound 3b; and (d) PLS-DA
scores plot for HepG2 cellular metabolites after treatment with compound 3b at 0, 2.5, and 10 µM.
The results of the validation experiments, five flasks of HepG2 with both compound 3b and
diflunisal, each analyzed in triplicate (15 vs. 15) are shown in Figure 4. The PCA scores plot shows
a separation of compound 3b and diflunisal metabolic effects on HepG2 cells. In t is unsupervised
analysis, the differential metabolic effects of compound 3b and diflunisal on HepG2 cells at 10 µM
can clearly be seen. As in the discovery experiment, compound 3b and diflunisal are separated in the
PLS-DA score plot (Figure 4). The cross-validation analysis (Figure 4) shows that the PLS-DA model
was valid.
Forty-two cellular metabolites were statistically significantly altered in HepG2 and Hep3B cells,
of which 38 eluted in the GCMS as single peaks and three (ethanolamine, glycine, and lysine) as
two peaks due to double chemical derivatives and one (galactose) as two peaks due to formation of
O-methyloxime (R)- and (S)-geometric isomers. In these cases, peak areas were summed to yield PAR
values for multivariate data analysis. In HepG2 cells, seven cellular metabolites were statistically
significantly attenuated and 16 were statistically significantly upregulated (Table 1). The pattern of
affected cellular metabolites was somewhat different in Hep3B, with 23 cellular metabolites attenuated,
but only four (glyceric acid, fructose 6-phosphate, glucose 6-phosphate, and guanosine) upregulated.
Interestingly, two of these metabolic upregulations (glucose 6-phosphate and fructose 6-phosphate)
were also observed in HepG2 cells. Of the 23 metabolites attenuated by compound 3b in Hep3B cells,
only one (creatinine) was also attenuated by compound 3b in HepG2 cells.
Metabolites 2017, 7, 23 6 of 16
Metabolites 2017, 7, 23 6 of 16 
 
 
Figure 4. Metabolomic analysis of HepG2 cellular metabolites after treatment with compound 3b and 
diflunisal in validation experiments. (a) Principal components analysis (PCA) scores plot showing the 
separation of metabolomic data from five culture flasks with compound 3b and five with diflunisal 
(control), each analyzed in triplicate. Filled symbols represent compound 3b and open symbols 
represent diflunisal; (b) PLS-DA scores plot for HepG2 cellular metabolites after treatment with 
compound 3b at 10 μM in validation experiments. Filled symbols represent compound 3b and open 
symbols represent diflunisal; (c) leave-one-out cross-validation of PLS-DA model where R2 is the 
correlation coefficient and Q2 is the predictability coefficient, showing that the PLS-DA model is valid. 
2.2. Metabolic Networks Modified by Compound 3b 
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networks derived from the HepG2 data. 
2.2.1. Purine and Pyrimidine Metabolism 
Cell proliferation requires de novo synthesis of purine and pyrimidine nucleotides to sustain not 
only DNA replication, but also the RNA synthesis, which is required for protein synthesis, particularly 
during the S-phase of the cell cycle [19]. This involves a high turnover of ATP and proliferating cells 
usually maintain ATP concentrations above 1 mM [19,20] to provide both cellular energy and for the 
synthesis of precursors of RNA and DNA. When cells do not maintain sufficient ATP synthesis by 
mitochondrial oxidative phosphorylation, they can fail to complete the cell cycle by stalling at either 
G1 or at G2-M [21]. Conversely, it is expected that agents which reduce cell proliferation will 
concomitantly diminish the cellular ATP pool. Figure 5 reveals that compound 3b treatment of HepG2 
Figure 4. Metabolomic analysis of HepG2 cellular metabolites after treatment with compound 3b and
diflunisal in validation experiments. (a) Principal components analysis (PCA) scores plot showing the
separation of metabolomic data from five culture flasks with compound 3b and five with diflunisal
(control), each analyzed in triplicate. Filled symbols represent compound 3b and open symbols
represent diflunisal; (b) PLS-DA scores plot for HepG2 cellular metabolites after treatment with
compound 3b at 10 µM in validation experiments. Filled symbols represent compound 3b and open
symbols represent diflunisal; (c) leave-one-out cross-validation of PLS-DA model where R2 is the
correlation coefficient and Q2 is the predictability coefficient, showing that the PLS-DA model is valid.
2.2. Metabolic Networks Modified by Compound 3b
Untargeted metabolomic analyses were empl yed to f r which meta olic networks were
modified by compound 3b in cell culture. Additionally, sin a larger umber of upregulated
metabolite w e found in HepG2 cells compared to Hep3B cells, most insights into metabolic networks
derived from the HepG2 data.
2.2.1. Purine and Pyrimidine Metabolism
Cell proliferation requires de novo synthesis of purine and pyrimidine nucleotides to sustain not
only DNA replication, but also the RNA synthesis, which is required for protein synthesis, particularly
during the S-phase of the cell cycle [19]. This involves a high turnover of ATP and proliferating cells
usually maintain ATP concentrations above 1 mM [19,20] to provide both cellular energy and for the
synthesis of precursors of RNA and DNA. When cells do not maintain sufficient ATP synthesis by
mitochondrial oxidative phosphorylation, they can fail to complete the cell cycle by stalling at either G1
or at G2-M [21]. Conversely, it is expected that agents which reduce cell proliferation will concomitantly
Metabolites 2017, 7, 23 7 of 16
diminish the cellular ATP pool. Figure 5 reveals that compound 3b treatment of HepG2 cells increased
intracellular levels of the ATP metabolite hypoxanthine. Although statistically significant, this increase
was +6% and, thus, may be of minor biological significance. Although intracellular concentrations
of the two purines xanthine and guanine were also determined in this study, they were unaltered by
compound 3b treatment. The pyrimidine uracil and its ribonucleoside uridine were also increased in
HepG2 cells by compound 3b treatment (Figure 5), by +31% and +15%, respectively. It is unlikely that
this is due to de novo pyrimidine synthesis since this is closely tied to the activity of the cell cycle [22].
It is more likely to result from increased RNA turnover and nucleoside salvage as cells enter apoptosis
in response to compound 3b [13].
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2.2.2. Glutathione Synthesis and Breakdown
Reduced glutathione (GSH, L-γ-glutamyl-L-cysteinylglycine) is a tripeptide that is formed from
glutamic acid, cysteine, and glycine that acts as an antioxidant and reducing agent controlling the
cellular redox state. It has also been proposed that glycine may protect the cell by conjugating
potentially toxic acids and making them available for deportation [23,24]. The presence of reactive
oxygen species (ROS) depletes GSH, oxidizing it to its dimer GSSG, which can be reduced back to
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GSH by the action of glutathione reductase (GR). Over-expression of GR in HepG2 cells has been
reported to ameliorate levels of ROS generated from H2O2 and restore GSH levels and cellular viability
by impairing apoptosis [25]. Studies have established that GSH depletion and post-translational
modification of proteins by glutathionylation are critical regulators of apoptosis [26]. Figure 6
shows the sequential addition of glutamic acid, cysteine and glycine in the de novo synthesis of
GSH. Intracellular concentrations of all three amino acid precursors in HepG2 cells were statistically
significantly enhanced by compound 3b, by +10.7%, +21.9%, and +15.3%, respectively. Furthermore,
5-oxo-proline, which is a metabolite of GSH that is recycled to glutamic acid [27], was also enhanced
+13% in HepG2 cells. As Figure 6 shows, glutathione anabolism and catabolism both appear to have
been upregulated by compound 3b. It should be noted that three of the reactions shown in Figure 6
require ATP and, therefore, may contribute to increased ATP and adenine turnover, with concomitant
elevation of cellular hypoxanthine (Figure 5).
The effect of compound 3b on cellular levels of total glutathione (reduced, GSH and oxidized,
GSSG) in HepG2 cells was also investigated. Interestingly, total glutathione in compound 3b-treated
cells was statistically significantly lower than in diflunisal-treated cells (Figure 5). Presumably,
compound 3b increased glutathione catabolism (green arrows) at the expense of glutathione anabolism
(red arrows) leading to increased intracellular 5-oxoproline and glutamic acid. It should be noted
that the mean difference in 5-oxoproline concentration was greater than the differences in the GSH
precursors glutamate, cysteine, and glycine (Figure 6).
Metabolites 2017, 7, 23 8 of 16 
 
to ameliorate levels of ROS generated from H2O2 and restore GSH levels and cellular viability by 
impairing apoptosis [25]. Studies have established that GSH depletion and post-translational 
modification of proteins by glutathionylation are critical regulators of apoptosis [26]. Figure 6 shows 
the sequential addition of glutamic acid, cysteine and glycine in the de novo synthesis of GSH. 
Intracellular concentrations of all three amino acid precursors in HepG2 cells were statistically 
significantly enhanced by compound 3b, by +10.7%, +21.9%, and +15.3%, respectively. Furthermore, 
5-oxo-proline, which is a metabolite of GSH that is recycled o glutamic acid [27], was also e hanced 
+13% in HepG2 cells. As Figure 6 shows, glutathione anabolism and catabolism both appear to have 
been upregulated by compound 3b. It should be noted that three of the reactions shown in Figure 6 
require ATP and, therefore, may contribute to increased ATP and adenine turnover, with 
concomitant elevation of cellular hypoxanthine (Figure 5).  
The effect of compound 3b on cellular levels of total glutathione (reduced, GSH and oxidized, 
GSSG) in HepG2 cells was also investigated. Interestingly, total glutathione in compound 3b-treated 
cells was statistically significantly lower than in diflunisal-treated cells (Figure 5). Presumably, 
compound 3b increased glutathione catabolism (green arrows) at the expense of glutathione 
anabolism (red arrows) leading to increased intracellular 5-oxoproline and glutamic acid. It should 
be noted that the mean differe ce in 5-oxoproline concentration was greater than the differences in 
the GSH precursors glutamate, cysteine, and glycine (Figure 6). 
 
Figure 6. Upregulation of the glutathione cycle in HepG2 cells by compound 3b. Anabolic reactions are 
shown in red. Catabolic reactions are shown in green. PAR means peak area ratio (relative 
concentration). Horizontal lines represent medians. * means p < 0.05; ** means p < 0.01; and **** means  
p < 0.0001. 
2.2.3. Energy Metabolism by Glycolysis and the Pentose Phosphate Pathway 
Glycolysis is a non-oxygen-requiring, energy-generating pathway converting glucose to pyruvate 
through a number of intermediates, the first two of which are glucose 6-phosphate (G6P) and fructose 
6-phosphate (F6P) [28]. When pyruvate is subsequently used for mitochondrial oxidation, the process 
is referred to as mitochondrial oxidation. When pyruvate is reduced instead to lactate or 
transaminated to alanine, this pathway is known as aerobic glycolysis, as happens in malignant 
tumors and cancer cell lines, often referred to as the Warburg effect. HepG2 cells have the capacity for 
Figure 6. Upregulation of the glutathione cycle in HepG2 cells by compound 3b. Anabolic reactions
are shown in red. Catabolic reactions are shown in green. PAR means peak area ratio (relative
concentration). Horizontal lines represent medians. * means p < 0.05; ** means p < 0.01; and **** means
p < 0.0001.
2.2.3. Energy Metabolism by Glycolysis and the Pentose Phosphate Pathway
Glycolysis is a non-oxygen-requiring, energy-generating pathway conver ing glucose to pyruvate
through a number of intermediates, the first two of which are glucose 6-phosphate (G6P) and fructose
6-phosphate (F6P) [28]. When pyruvate is subsequently used for mitochondrial oxidation, the process
is referred to as mitochondrial oxidation. When pyruvate is reduced instead to lactate or transaminated
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to alanine, this pathway is known as aerobic glycolysis, as happens in malignant tumors and cancer cell
lines, often referred to as the Warburg effect. HepG2 cells have the capacity for aerobic glycolysis [17].
Glycolysis also serves as the starting point for the pentose phosphate pathway (PPP), which generates
NADPH for use in biosynthetic reactions and also pentoses, such as ribose [29]. Figure 7 shows that
glycolytic intermediates G6P and F6P are upregulated in HepG2 cells by compound 3b, both by +62%.
These glycolytic intermediates were also upregulated by compound 3b in Hep3B cells (Table 1). In the
PPP, ribose was upregulated +24% by compound 3b in HepG2 cells, while sedoheptulose 7-phosphate
was increased +53% in HepG2 cells and +12.7% in Hep3B cells. There were no statistically significant
differences in the cellular concentrations of the glycolytic end-products pyruvate, lactate, or alanine
due to compound 3b treatment of either cell line. Moreover, none of the measured tricarboxylic acid
cycle intermediates [29], citrate, succinate, or 2-oxoglutarate, were altered by compound 3b treatment,
suggesting no effect on mitochondrial oxidation of pyruvate. The effects observed, therefore, appeared
to be restricted to the proximal end of glycolysis and the PPP. However, it is conceded that the elevation
in cellular ribose concentration, like uracil and uridine, may be due to the salvage of RNA components
after nucleic acid digestion in apoptosis or autophagy.
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2.2.4. Pantothenic Acid Transport and Fatty Acid β-Oxidation
Pantothenic acid is a mammalian vitamin that is transported into cells by a multivitamin
transporter. It is present in the cell culture medium e ployed. The role f pa tothenic acid is
as an obligatory precursor for coenzyme A, which is used in many metabolic reactions, includ ng the
degradation of fatty acids by mitochondrial β-oxidation. The observed increase of +18% pantothenic
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acid in HepG2 cells treated with compound 3b appeared not to be associated with increasedβ-oxidation
of fatty acids that might be due to increased coenzyme A synthesis. Palmitic, stearic, and oleic acid
cellular concentrations were unaltered (Figure 8). Interestingly, arachidonic acid was increased >40-fold
after treatment with diflunisal (data not shown). Diflunisal is a prostaglandin E synthesis inhibitor [30]
and, thus, expected to elevate arachidonic acid concentrations. Compound 3b does not share this
property of the parent compound.
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Figure 8. (a) Increased cellular concentration of pantothenic acid with no concomitant reduction in fatty
acid concentrations in HepG2 cells after treatment with compound 3b relative to diflunisal. Intracellular
concentrations of palmitic acid (b), stearic acid (c), and oleic acid (d) were unaltered. Horizo tal lines
represent medians. **** means p < 0.0001.
2.3. Effect of Compound 3b and Diflunisal on HepG2 and Hep3B Cell Viability
The published data on the cytotoxicity of compound 3b and its parent diflunisal were derived from
exposure of hepatoma cell lines to the compounds in culture for 72 h [13]. To examine the effect of these
two compounds on the viability of HepG2 and Hep3B cells under the conditions used in the metabolomic
investigations, cell viability after 24 h exposure was conducted. As shown in Figure 9, the effect of both
compound 3b and diflunisal was less after 24 h than the published values of cytotoxicity at 72 h [13].
This is not surprising since the doubling times in our hands of HepG2 and Hep3B cells were 40 h and
25 h, respectively. Compound 3b was cytotoxic to both HepG2 and Hep3B cells (Figure 9), showing
a monophasic exponential decline in cell viability over the range of concentrations, 0.4, 2.0, 10.0, 50.0,
and 250 µM. However, at the concentration used in the metabolomic experiments (10 µM), cell viability at
24 h was >90%. In contrast, diflunisal only showed toxicity at 250 µM, with a plateau in cell viability from
0.4 to 50.0 µM. Although the differences in cytotoxicity after 24 h between compound 3b and diflunisal
were difficult to observe at 10 µM, clear perturbations of the cellular metabolome in both cell lines were
observed at this concentration. This underscores the power of metabolomics in revealing changes in cell
phenotype that might not be apparent at the whole cell level.
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cytotoxic response for diflunisal with HepG2 cells; and (d) a plateau cytotoxic response for diflunisal
with Hep3B cells with cytotoxicity only observed at 250 µM.
3. Discussion
In an attempt to address perceived issues in the pharmaceutical industry, it has recently been
proposed to include metabolomics as a “routine component of the drug discovery process . . . to provide
feedback on the in vivo mechanism of action” [31]. A workflow using NMR-based metabolomics
was proposed that was envisaged as improving the efficiency and success rate of drug discovery [31].
These concepts have been further developed in which metabolomics was envisaged to have utility in
biomarker identification, mechanism of action, drug candidate efficacy and safety, patient selection and
stratification, and treatment and patient follow-up, all assisting in the drug discovery and development
process [32]. It is in the spirit of these recent discussions that we undertook a metabolomic investigation
of the lead molecule compound 3b compared to its parent molecule diflunisal. Additionally, we used
target cells for this molecule, two hepatoma cell lines with widely different cell biologies [33]—HepG2
and Hep3B—in an effort to unmask metabolic information pertinent to this drug’s mode of action.
The lead molecule compound 3b affected metabolic pathways differently in the two hepatoma cell
lines. There are many examples of differential responses to drugs by these two cell types. The underlying
mechanisms of this have been discussed in detail [33] and are in part based upon the observations
that HepG2 is hepatitis B virus (HBV)-negative and non-tumorigenic, while Hep3B is HBV-positive
and tumorigenic. Moreover, RAS signaling is low in HepG2 and high in Hep3B. Additionally, HepG2
cells are positive for the expression of the p53 tumor suppressor protein but negative for expression of
cyclooxygenase 2 (COX2). In contrast, Hep3B cells do not express p53 protein but do express COX2.
Many of the differences in gene expression in these two cell lines are due to the HBx protein, a pleiotropic
regulator of gene expression involved in the development of HCC [33].
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The issue of dose-dependency of the metabolic effects of compound 3b was addressed. Both
HepG2 and Hep3B cells responded to compound 3b in a dose-dependent manner. The metabolomic
phenotype for 2.5 µM compound 3b overlapped with the metabolomic phenotype of untreated cells
in both cell lines, while the metabolomic phenotype for 10 µM compound 3b was distinct from the
control and 2.5 µM phenotypes for both cell lines. These findings, which represent the metabolic
reprogramming of hepatoma cells when cultured with compound 3b, are in agreement with the
published dose-dependency efficacy data for the antiproliferative effects of compound 3b in both cell
lines [13]. Here, the metabolomic data garnered for compound 3b was in agreement with the limited
information regarding its biological properties.
These investigations produced novel insights into the pharmacology of compound 3b beyond
its dose-dependent effects in HepG2 and Hep3B cells. It is surprising that so few of the metabolic
perturbations elicited by the drug were common to both cell types. Moreover, in most cases when a
metabolite was altered in both cell types, the direction of change was converse (5-oxoproline, cysteine,
glutamate, lysine, and tyrosine). In only three cases was a metabolite altered in the same direction in
both cell lines (creatinine, F6P, and G6P). This may indicate that compound 3b has an effect on both the
urea cycle (where creatinine is ultimately synthesized from arginine) and glycolysis and the pentose
phosphate pathway (where G6P and F6P are produced). This underscores the importance of using
more than one cell culture model in metabolomic investigations.
As has been stated earlier, pantothenic acid is not produced by mammalian cells, but rather
is a vitamin that is transported into HepG2 cells by a sodium-dependent multivitamin transporter
(SMVT) [34–36] that is encoded by the SLC5A6 gene [36]. It is surmised that compound 3b increases
CoA synthesis by enhancing SLC5A6 activity to increase pantothenic acid transport from the culture
medium, where it is present at a concentration of 16.8 µM. SLC5A6 accounts for 98.6% of pantothenic
acid uptake across the human blood-brain barrier and has been studied in detail in a human
microvascular endothelial cell line [37]. The most potent drug inhibitors of SLC5A6 were reported
to be NSAIDs, including indomethacin, ketoprofen, diclofenac, ibuprofen, phenylbutazone, and
flurbiprofen [37]. Diflunisal is an NSAID and, thus, is therefore potentially a greater inhibitor
of pantothenic acid uptake by HepG2 cells than compound 3b. Given the free fatty acid profiles
determined in this investigation, it appears unlikely that the elevated pantothenic acid translated
through elevated coenzyme A synthesis to enhanced fatty acid β-oxidation.
An untargeted GCMS-based metabolomic investigation of the effects of compound 3b and
diflunisal permitted conclusion that the lead compound upregulated the following pathways—purine
and pyrimidine catabolism, the glutathione cycle, together with energy metabolism through glycolysis
and the pentose phosphate pathway. The lead compound 3b displayed clear differences in metabolic
effects from the parent diflunisal in both HepG2 and Hep3B hepatoma cells. Although both compounds
appeared to be similarly cytotoxic with 24 h culture at 10 µM, metabolomics revealed changes in
underlying metabolic mechanisms that presaged impending cytotoxicity due to compound 3b. These
findings are novel, not only in relation to compound 3b, but also to the effects of drugs on hepatoma
cells in general. Future studies of drug effects on cultured tumor cells should include a metabolomic
component in order to understand the effect of the drugs on intermediary metabolism, especially if such
studies are part of a high-throughput screening protocol within the drug discovery and development
process [31,32].
It is very likely that novel antiviral and anticancer drugs leave a unique metabolomic footprint
on target cells. This was recently demonstrated in a metabolomic study of the antiproliferative
effects of physapubenolide, a withanolide first isolated from Physalis pubescens of the nightshade
family. Treatment of HepG2 cells with physapubenolide, followed by GCMS-based metabolomic
analysis, resulted in the detection of a decreased lactate production, which led the authors to a precise
mechanism of action of this potential new drug involving the Akt-p53 pathway [14]. Furthermore,
metabolomics has been successfully employed in the discovery of a novel antibiotic, 7-prenylisatin,
which was isolated from Streptomyces sp. MBT28, following a strategy based upon NMR-based
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metabolomics. This new drug candidate, which showed activity against Bacillus subtilis, was shown to
be produced from tryptophan by indole prenyltransferase [15]. Metabolomics can, therefore, provide a
new toolbox in the field of medicinal chemistry.
4. Materials and Methods
4.1. Drugs
Diflunisal and 2′,4′-difluoro-4-hydroxy-N′-[(pyridin-2-yl)methylidene]biphenyl-3-carbohydrazide
(compound 3b) were previously described [13]. Stock solutions in dimethylsulfoxide (DMSO) were
prepared for addition to the cell cultures to yield final concentrations of 0, 2.5 and 10 µM. These
concentrations were chosen on the basis of the published IC50 values for cell growth inhibition of
compound 3b in HepG2 cells and Hep3B cells of 10.3 and 16.2 µM, respectively [13].
4.2. Cell Culture, Drug Treatment, and Harvesting of Intracellular Contents
HepG2 and Hep3B cell lines were purchased frozen from ATCC (LCG Standards GmbH, Wesel,
Germany). Both cell lines were tested for mycoplasma contamination and only lines testing negative
were used in the study. Cells were cultured to 90% confluence in T75 culture flasks in DMEM containing
10% FBS and 100 U/mL penicillin/100 mg/mL streptomycin (Life Technologies, Carlsbad, CA, USA),
as described [17,38], then split 3:1 and subcultured in T75 flasks. The concentration of the energy
molecules D-glucose and L-glutamine in the medium was 25 and 4 mM, respectively.
In discovery experiments, both HepG2 and Hep3B cells were exposed in culture to compound
3b and diflunisal at 0, 2.5 and 10 µM concentrations for 24 h, with four flasks at each concentration.
In validation experiments, a further six flasks of HepG2 cells were exposed in culture for 24 h to
10 µM compound 3b and six flasks of HepG2 cells to 10 µM diflunisal, five of which were used for
metabolomic investigations. The cells were then harvested for analysis. Adherent cells were removed
by gentle scraping, washed twice with ice-cold PBS, spun, resuspended in ice-cold distilled water and
briefly sonicated to liberate water-soluble metabolites as described.
4.3. Cell Viability Assay and Cellular Protein Determination
HepG2 and Hep3B cell viability was assessed in culture using a resazurin assay where the
virtually nonfluorescent blue resazurin is reduced to the highly-fluorescent compound resorufin by
dehydrogenase enzymes in metabolically-active cells, generating a quantitative measure of viability.
Briefly, resazurin (0.01 mg/mL) (Sigma-Aldrich) was added to the culture medium and incubated for
1 h. Fluorescence as an indicator of cell viability was measured (excitation 545 nm, emission 590 nm)
with a Tecan Infinite® 200 plate reader and I-control software. Untreated cells were used to generate
the 100% viability values.
Protein determinations were made by the Bradford method using commercial reagents (Bio-Rad,
Cressier, Switzerland) according to the manufacturer’s instructions that yielded a linear calibration
(R2 = 0.994). Aqueous extracts of HepG2 and Hep3B cells had protein concentrations in the range
2–18 µg/µL.
4.4. Gas Chromatography-Mass Spectrometry (GCMS) Analysis
Aliquots of aqueous intracellular extracts (50 µL) were subjected to GCMS analysis with
4-chlorophenylacetic acid (2 mM; 100 µL) as internal standard using a slight modification of our
published methods [6,16,17]. Samples were treated with an equal volume of ultrapure pyridine
and then blown to dryness under N2 and derivatized with methoxyamine hydrochloride (MOX)
and BSTFA/TMCS as described [6]. Samples (1.0 µL) were injected in duplicate for the discovery
experiment, and in triplicate for the validation experiment using an Agilent 7683B liquid sampler into
an Agilent 6890N gas chromatograph with an Agilent 5975B mass selective detector operating under
electron impact ionization at 70 eV. The front inlet was operated in splitless mode at 250 ◦C and an
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HP5-MS column (60 m; i.d. 250 µm; film thickness 0.25 µm) subjected to a temperature program of
70 ◦C for 3 min, 10 deg/min to 250 ◦C, 10 deg/min to 300 ◦C, held for 8 min (run time 34 min). Mass
spectra were collected from m/z 35.0 to 650.0.
In each 34 min chromatogram, in addition to background peaks and the internal standard,
63 peaks deriving from 58 discrete metabolites were identified by comparison of their mass spectra
with the NIST 14 Library (MS Wil GmbH, Wil, Switzerland) that contains 276,248 mass spectra from
242,466 compounds and by comparison of their retention times with an in-house collection of 120
authentic standards.
Each annotated peak was quantitated as a peak area ratio (PAR) from its peak area/internal
standard peak area using AutoQuant in the on-board Agilent ChemStation software, followed by
QuantBrowser GCMS software (Leoson BV, Middelburg, The Netherlands). The resulting spreadsheet
of PARs, normalized against protein content, for each annotated metabolite for both cell line lysates
treated with diflunisal and compound 3b at each of three concentrations (0, 2.5, and 10 µM) was
imported into SIMCA 14 (MKS Data Analytics Solutions, Malmö, Sweden). Multivariate data
analysis using unsupervised PCA, supervised PLS-DA, with leave-one-out cross validation of PLS-DA
model, and OPLS-DA were conducted as described [6]. Univariate statistics was performed using
GraphPad Prism 6.07 (GraphPad Software, Inc., La Jolla, CA, USA). For statistical evaluation of three
concentrations (0, 2.5, and 10 µM), analysis of variance with Bonferroni’s multiple comparisons test
was used, except where unequal variances occurred, then the nonparametric Kruskal-Wallis test with
Dunn’s multiple comparisons test was used. For pairwise analyses, for example between 10 µM
diflunisal and 10 µM compound 3b, the nonparametric Mann-Whitney U test was used. All statistical
significances were expressed as two-tailed p values, where * means p = 0.01–0.05, ** means p < 0.01,
*** means p < 0.001, and **** means p < 0.0001.
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